The mechanism by which alpelisib improves blood glucose levels in CHI patients likely relates to its inhibition of the PI3K-AKT pathway, which is a key pathway in the insulin signaling cascade. The gene discussed is AKT1; the disease is congenital isolated hyperinsulinism.